The Heterochronic Optimized Plasma Exchange (HOPE ™) Trial
The solution is a personalized multi-therapy – unique to each patient’s pathology and genetics. The solution includes:
- Therapeutic plasma exchange to remove toxic aged plasma, replaced with
- Curated youth factor plasma, and
- Personalized trophic factors
By using the MaxWell Brain ™ MAP (MAP= Multifactorial Analysis and Plan) software created by David Haase, MD, physicians are assisted in sorting the tens of thousands of data points that describe human neurologic function to prioritize the application of multi-therapies which are devised to help that unique individual. This personalized approach has shown great promise for slowing, stopping, or even reversing neurocognitive decline.
MaxWell scientists and physicians have developed a patent-pending plasma exchange protocol in which the patient’s plasma is removed for study and replaced with a contract manufactured and optimized plasma product which will be submitted to the FDA as a new Alzheimer’s biologic drug. The new biologic, code named PlasmaX, is collected from a curated, young donor registry and fractionated via an FDA approved manufacturing process to remove microbes, cellular material, HLA antibodies, blood type markers and prions while maintaining appropriate levels of proteins, protease inhibitors and coagulation factors.
The combined therapy will be studied in the HOPE for Alzheimer’s trial, scheduled for 2019. We hope HOPE to be therapeutic for Alzheimer’s as well as other chronic, degenerative conditions. HOPE is an intensive multi-week protocol which includes all of the above in addition to targeted metabolic, pharmaceutical, and biologic therapies, individualized neuro-stimulation, neuro-therapy, a controlled diet and lifestyle coaching.